Business Description
Pelthos Therapeutics Inc
NAICS : 541713
SIC : 8731
ISIN : US1711262048
Total Employee Number:
92Description
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.2 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 0.76 | |||||
Debt-to-EBITDA | -0.52 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -113.1 | |||||
3-Year EPS without NRI Growth Rate | -109.3 | |||||
3-Year FCF Growth Rate | -112.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 115.88 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.61 | |||||
9-Day RSI | 59.36 | |||||
14-Day RSI | 59.1 | |||||
3-1 Month Momentum % | 19.48 | |||||
6-1 Month Momentum % | 5.68 | |||||
12-1 Month Momentum % | 132.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.79 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 1.28 | |||||
Days Inventory | 783.57 | |||||
Days Sales Outstanding | 125.38 | |||||
Days Payable | 148.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -77.6 | |||||
Shareholder Yield % | -14.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.15 | |||||
Operating Margin % | -157.7 | |||||
Net Margin % | -186.24 | |||||
EBITDA Margin % | -183.45 | |||||
FCF Margin % | -127.35 | |||||
OCF Margin % | -126.65 | |||||
ROE % | -212.22 | |||||
ROA % | -63.86 | |||||
ROIC % | -65.55 | |||||
3-Year ROIIC % | -26.23 | |||||
ROC (Joel Greenblatt) % | -218.53 | |||||
ROCE % | -85.1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.37 | |||||
PB Ratio | 2.79 | |||||
EV-to-EBIT | -1.78 | |||||
EV-to-EBITDA | -1.88 | |||||
EV-to-Forward-EBITDA | 4.55 | |||||
EV-to-Revenue | 3.45 | |||||
EV-to-Forward-Revenue | 1.52 | |||||
EV-to-FCF | -2.71 | |||||
Earnings Yield (Greenblatt) % | -56.18 | |||||
FCF Yield % | -34.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:PTHS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pelthos Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 27.701 | ||
| EPS (TTM) ($) | -20.64 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 86.02 | ||
| 14-Day RSI | 59.1 | ||
| 14-Day ATR ($) | 1.224321 | ||
| 20-Day SMA ($) | 27.453 | ||
| 12-1 Month Momentum % | 132.22 | ||
| 52-Week Range ($) | 11.206 - 54.29 | ||
| Shares Outstanding (Mil) | 3.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pelthos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pelthos Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-17 09:00 | In 172 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-13 08:00 | In 138 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 137 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 45 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 | 25.88 (-1.26%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:30 | 26.01 (-3.84%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 26.01 (-3.84%) | ||
| 38(th) Annual ROTH Conference | 2026-03-23 15:00 | 20.74 (-7.99%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 08:00 | 24.08 (-3.68%) | ||
| Annual report for 2025 | 2026-03-19 | 24.08 (-3.68%) |
Show
Entries
Pelthos Therapeutics Inc Frequently Asked Questions
What is Pelthos Therapeutics Inc(PTHS)'s stock price today?
The current price of PTHS is $29.03. The 52 week high of PTHS is $54.29 and 52 week low is $11.21.
When is next earnings date of Pelthos Therapeutics Inc(PTHS)?
The next earnings date of Pelthos Therapeutics Inc(PTHS) is 2026-08-13 Est..
Does Pelthos Therapeutics Inc(PTHS) pay dividends? If so, how much?
Pelthos Therapeutics Inc(PTHS) does not pay dividend.
Guru Commentaries on AMEX:PTHS
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Pelthos Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers